Sensorion

ALSEN.PAPhase 3

Sensorion's mission is to find solutions for hearing disorders by building a portfolio of innovative therapies through its three strategic pillars: Restore, Treat, and Prevent. The company leverages a unique internal R&D platform to advance its pipeline, with key assets like OTOF-GT in Phase 1/2 and SENS-401 in Phase 2. Its clear strategy focuses on addressing a large, underserved market in inner ear diseases through both proprietary development and strategic partnerships.

Market Cap

$369.3M

Employees

50-100

Focus

Small Molecules

ALSEN.PA · Stock Price

USD 0.62+0.10 (+19.62%)

Historical price data

AI Company Overview

Technology Platform

A proprietary, integrated R&D platform for inner ear disorders, enabling the discovery and development of both AAV-based gene therapies and small molecules targeting auditory hair cell and neuron protection and repair.

Pipeline Snapshot

6 drugs in pipeline, 1 in Phase 3

Drug	Indication	Stage
SENS-401 + SENS-401	Severe Sudden Sensorineural Hearing Loss	Phase 2/3
SENS-401 (R-Azasetron Besylate)	Hearing Loss	Phase 2
SENS-111 100mg + SENS-111 200mg + Placebo Oral Tablet	Acute Unilateral Vestibulopathy (AUV)	Phase 2
SENS-401 (R-Azasetron Besylate)	Hearing Loss Ototoxic	Phase 2
SENS-218	Inner Ear Diseases	Phase 1

Funding History

Total raised: $78M

PIPE$25MUndisclosedSep 15, 2020

IPO$30MUndisclosedApr 16, 2015

Series B$15MUndisclosedJun 15, 2013

Series A$8MUndisclosedJun 15, 2009

Opportunities

The primary growth opportunity lies in successfully developing the first approved disease-modifying therapies for hearing loss, capturing a multi-billion dollar market with high unmet need.

Strategic partnerships for SENS-401 in larger indications like SSNHL could provide non-dilutive funding and validate the platform.

Expansion of the gene therapy pipeline to other genetic targets represents a long-term opportunity.

Risk Factors

Key risks include clinical trial failures, particularly for the novel intracochlear gene therapy delivery; regulatory uncertainty in defining endpoints for hearing restoration; intense competition from well-funded peers; and dependence on capital markets for funding as a pre-revenue company.

Competitive Landscape

Main competitors include Decibel Therapeutics (Regeneron) and Akouos (Eli Lilly) in gene therapy, and Frequency Therapeutics in hair cell regeneration. Sensorion differentiates through its balanced pipeline of both gene therapies and small molecules, deep internal otology expertise, and advanced clinical position with OTOF-GT.